Acute Lymphoblastic Leukemia (ALL) PCR Panel, tap a thumbnail to see more views.
Acute Lymphoblastic Leukemia (ALL) PCR Panel
The TRUPCR® ALL PCR Panel Kit is an advanced, real-time PCR-based diagnostic tool designed for the qualitative detection of critical fusion gene transcripts associated with acute lymphoblastic leukemia (ALL). This comprehensive assay enables the identification of diagnostic and prognostic markers from peripheral blood or bone marrow samples, supporting more informed clinical decisions in both pediatric and adult ALL cases. ALL is primarily a childhood leukemia, often driven by chromosomal translocations that produce pathogenic fusion genes disrupting normal lymphoid development. These alterations commonly involve transcription factors and signaling molecules that promote leukemic cell proliferation and survival. The TRUPCR® ALL PCR Panel is developed to detect a wide range of clinically relevant fusion transcripts including BCR-ABL1, TEL-AML1, E2A-PBX1, and multiple MLL-rearrangements, which are essential for risk stratification, prognosis, and therapeutic direction. This kit includes reagents for both cDNA synthesis and target amplification, enabling full RNA-to-result workflow in a single package.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
The TRUPCR® ALL PCR Panel Kit is an advanced, real-time PCR-based diagnostic tool designed for the qualitative detection of critical fusion gene transcripts associated with acute lymphoblastic leukemia (ALL). This comprehensive assay enables the identification of diagnostic and prognostic markers from peripheral blood or bone marrow samples, supporting more informed clinical decisions in both pediatric and adult ALL cases.
ALL is primarily a childhood leukemia, often driven by chromosomal translocations that produce pathogenic fusion genes disrupting normal lymphoid development. These alterations commonly involve transcription factors and signaling molecules that promote leukemic cell proliferation and survival. The TRUPCR® ALL PCR Panel is developed to detect a wide range of clinically relevant fusion transcripts including BCR-ABL1, TEL-AML1, E2A-PBX1, and multiple MLL-rearrangements, which are essential for risk stratification, prognosis, and therapeutic direction.
This kit includes reagents for both cDNA synthesis and target amplification, enabling full RNA-to-result workflow in a single package.
- Detects 15+ clinically relevant ALL fusion transcripts
- Sensitivity down to 10 copies of target RNA
- Complete cDNA + PCR chemistry in one kit
- Compatible with leading real-time PCR systems
Sensitive Real-Time PCR Detection of Acute Lymphoblastic Leukemia (ALL) Fusion Transcripts
The TRUPCR® Acute Lymphoblastic Leukemia (ALL) PCR Panel Kit is an advanced, real-time RT-PCR-based assay for the qualitative detection of major fusion gene transcripts associated with acute lymphoblastic leukemia. This kit enables early and accurate identification of key diagnostic and prognostic markers from peripheral blood or bone marrow samples, supporting effective disease classification and personalized therapy in ALL.
Designed for comprehensive coverage, the ALL PCR panel detects critical fusion variants such as BCR-ABL1 (p190/p210/p230), TEL-AML1, E2A-PBX1, and multiple MLL rearrangements, providing clinicians and researchers with a complete genetic profile of the disease. The assay offers high sensitivity, capable of detecting as few as 10 copies of fusion transcripts, and includes reagents for both cDNA synthesis and amplification.
The TRUPCR® ALL PCR Panel is ideal for clinical laboratories, diagnostic centers, and translational research settings aiming to streamline ALL testing with a rapid, robust, and reliable workflow.
Molecular Background
Acute lymphoblastic leukemia (ALL) is a hematological malignancy that originates from immature lymphoid cells and is most common in children. Recurrent chromosomal translocations-such as t(9;22), t(12;21), t(1;19), and MLL gene fusions-result in oncogenic fusion transcripts that drive leukemogenesis. These genetic alterations block normal B- or T-cell differentiation and promote uncontrolled cell proliferation.
Molecular characterization of these fusions is critical for accurate diagnosis, risk stratification, and treatment monitoring. The TRUPCR® ALL PCR Panel allows detection of over 15 transcript variants across key ALL-associated genes.
Assay Performance & Utility
- Simultaneous detection of major diagnostic and prognostic fusion markers in ALL
- Accurate identification of p190, p210, and p230 BCR-ABL1 variants
- Covers multiple MLL rearrangements for detailed genetic profiling
- Minimal hands-on time with complete cDNA and PCR reagent mix
- Built-in ABL1 control ensures RNA quality and reaction validity
- Validated for routine clinical diagnostics and translational research
Technical Specifications
- Assay Type: Two-step RT-PCR (qualitative detection)
- Markers Detected: BCR-ABL1 (p190/p210/p230), TEL-AML1, E2A-PBX1, MLL-AF4, MLL-AF9, MLL-ENL
- Transcript Variants: 15+ fusion transcript types
- Sensitivity: Detects as low as 10 copies of target transcript
- Sample Type: Peripheral blood or bone marrow
- Input Material: cDNA synthesized from total RNA
- Controls: Internal ABL1 gene for RNA quality control
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Product Catalogus
Frequently paired with this kit
Other assays and instruments lab teams add alongside the Acute Lymphoblastic Leukemia (ALL) PCR Panel.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
